Setsuo Hirohashi
Papers
1
Total Citations
35
H-Index
1
About
Setsuo Hirohashi is a distinguished researcher whose work lies at the intersection of cancer biology and clinical biomarker discovery. His primary research areas include pancreatic cancer prognosis, drug response prediction, and the application of proteomics to identify clinically actionable molecular signatures. One of his most notable contributions is a landmark 2010 study on survival prediction for pancreatic cancer patients receiving gemcitabine treatment. In this work, Hirohashi employed liquid chromatography-mass spectrometry (LC-MS) to compare baseline proteomic profiles, successfully identifying novel biomarkers that could stratify patients by expected treatment benefit. This study, which has garnered 35 citations, addressed a critical clinical challenge: while gemcitabine remains a standard therapy for advanced pancreatic cancer, patient outcomes vary widely, and many derive little benefit. By pinpointing predictive biomarkers, Hirohashi’s research has paved the way for more personalized therapeutic strategies in a notoriously difficult-to-treat malignancy. His contributions exemplify the vital bridge between molecular profiling and real-world clinical decision-making, offering hope for improved survival outcomes through tailored cancer care.
Research Focus
Key Achievements
Top Papers
- 1